ModifiedBlue Cross Blue Shield - OklahomaPolicy CPCPLAB045

Pathogen Panel Testing (lab reimbursement/coding)

Reimbursement and coding criteria for multiplex and molecular pathogen panel testing in the outpatient setting for Blue Cross Blue Shield of Oklahoma; governs provider billing and reimbursement for specified panels and specimens.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyPathogen Panel Testing (lab reimbursement/coding)

Policy CodePolicy CPCPLAB045

Change TypeCode additions and reimbursement clarification

Effective DateOctober 1, 2025

Next Review DateN/A

Key ActionSubmit accurate documentation and supporting records upon request; claims are subject to review against plan documents and provider contracts.

SourceLink

POLICY UPDATE CHANGES

Added codes 0590U and 0593U effective 10/01/2025.

Added codes 0202U, 0223U, 0225U, and 0531U.

Added new CPT code 0528U effective 01/01/2025.

Added code 0416U on 03/01/2024.

Removed statements disallowing reimbursement for molecular-based panel testing for general screening and added specific examples and clarification that such screening tests are not reimbursable.

5maximum respiratory pathogens reimbursable

6+not reimbursable respiratory count

outpatient onlysetting restriction

30+codes listed

multiplecode change history

Coverage and Reimbursement Criteria

Outpatient pathogen panel reimbursement criteria

Reimbursement criteria and exclusions for outpatient molecular/multiplex pathogen panels.

ALL of the following

ALL of the following
- ALL of the following
  - ALL of the following
    Temperature ≥102° F
    Pronounced dyspnea
    Tachypnea

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyPathogen Panel Testing (lab reimbursement/coding)

Policy CodePolicy CPCPLAB045

Change TypeCode additions and reimbursement clarification

Effective DateOctober 1, 2025

Next Review DateN/A

Key ActionSubmit accurate documentation and supporting records upon request; claims are subject to review against plan documents and provider contracts.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

ANY of the following

Multiplex PCR-based panel testing of 6 or more respiratory pathogens (6+) is not reimbursable
Multiplex PCR-based panel testing of pathogens in cerebrospinal fluid (CSF) is not reimbursable
Molecular detection–based panel testing of pathogens in the blood is not reimbursable
Molecular detection–based panel testing of urine pathogens for diagnosis of urinary tract infections (example: GENETWORx Molecular PCR UTI Test) is not reimbursable
Molecular-based panel testing to screen for or diagnose wound infections (example: GENETWORx PCR Wound Testing) is not reimbursable
Molecular-based panel testing for general screening of microorganisms (example: MicroGenDX qPCR+NGS) is not reimbursable

Coverage criteria and billing rules (excerpted)

Reimbursement and coverage rules as amended in Policy Update History (selected highlights present in this document excerpt):

ALL of the following

This policy is specific to testing in the outpatient setting; statements in Reimbursement Information were revised to remove leading language 'In the outpatient setting.'

ANY of the following

Added codes 0590U and 0593U (listed 08/01/2025; effective 10/01/2025)
Added codes 0202U, 0223U, 0225U, and 0531U (listed 01/23/2025; summary notes 04/15/2025)
Added CPT code 0528U (listed 11/19/2024; effective 01/01/2025)
Added codes 0441U, 0442U, 0480U, 0504U and removed codes 0151U, 0416U (document entry 10/30/2024)
Added code 0416U (03/01/2024 entry)

ALL of the following

Document updated with literature review (10/30/2024 entry) and Reimbursement Information modified to indicate the policy is specific to outpatient testing
Boarding changes on 11/01/2023 removed and then restated specific examples clarifying that molecular-based panel testing for general screening of microorganisms is not reimbursable (examples include SmartJane™, UroSwab®, GENETWORx tests, MicroGenDX qPCR+NGS)

ALL of the following

Policy Update History enumerates additions and removals of multiple CPT/HCPCS codes; providers should refer to the coding section for the current list of applicable codes and effective dates

Procedure, CPT/HCPCS and Proprietary Codes

Listed procedure/CPT/HCPCS/proprietary codesmixed

87154
87483
87631
87632
87633
87636
87637
0068U
0086U
0109U

1–10 of 35

1/4

Notable U-code changesCPT | HCPCS | mixed

0590U	New code added effective 10/01/2025
0593U	New code added effective 10/01/2025
0528U	New CPT code added effective 01/01/2025
0416U	Added 03/01/2024; later removal noted 10/30/2024 entry

inv-05: Maximum reimbursable respiratory pathogens on multiplex PCR panel — Up to 5.

Maximum reimbursable pathogensUp to 5 respiratory pathogens on a multiplex PCR panel are eligible for reimbursement when clinical criteria are met

Non‑reimbursable thresholdPanels detecting 6 or more respiratory pathogens are not reimbursable under this policy

Clinical requirementReimbursement for up to 5‑pathogen respiratory panels requires signs/symptoms of respiratory infection (e.g., temperature ≥102°F, pronounced dyspnea, tachypnea, or tachycardia)

inv-06: outpatient_setting_only — Policy specific to testing in the outpatient setting (per 10/30/2024 update).

Setting restrictionPolicy is specific to testing in the outpatient setting; criteria do not apply to testing in other settings

Policy history noteOutpatient‑only statement was added/clarified in the 10/30/2024 update (Policy Update History entry)

Implication for billingReimbursement statements and listed code applicability should be interpreted for outpatient services only

Definitions and Test Scope

inv-09: Multiplex PCR-based panel testing (respiratory, up to 5) — testing modality that may be reimbursable for symptomatic respiratory ...

DefinitionMultiplex PCR‑based respiratory panel (up to 5 pathogens): testing modality that may be reimbursable for individuals displaying signs and symptoms of a respiratory tract infection

Required clinical signsAt least one qualifying sign: temperature ≥102°F, pronounced dyspnea, tachypnea, or tachycardia

SettingApplies to outpatient testing only

inv-10: Multiplex PCR-based panel testing (6+ respiratory) — not reimbursable under this policy.

DefinitionMultiplex PCR‑based respiratory panels that detect 6 or more pathogens are not reimbursable under this policy

Reference in policyExplicitly stated as non‑reimbursable in Reimbursement Information #2

Action for providersDo not bill or expect reimbursement for multiplex respiratory panels enumerating 6+ pathogens under this policy

inv-11: Specimen/indication exclusions — CSF panels, blood pathogen panels, urine UTI molecular panels, wound infection panels, and general microorganism screening exclusions.

CSF panelsMultiplex PCR‑based panel testing of pathogens in cerebrospinal fluid (CSF) is not reimbursable

Blood pathogen panelsMolecular detection‑based panel testing of pathogens in the blood is not reimbursable

Urine UTI molecular panelsMolecular detection‑based panel testing of urine pathogens for diagnosis of UTI (e.g., GENETWORx Molecular PCR UTI Test) is not reimbursable

Wound infection panelsMolecular‑based panel testing to screen for or diagnose wound infections (e.g., GENETWORx PCR Wound Testing) is not reimbursable

inv-12: Molecular-based panel testing (general screening) — molecular-based panel testing for general screening of microorganisms.

General screening panelsMolecular‑based panel testing for general screening of microorganisms (e.g., MicroGenDX qPCR+NGS) is not reimbursable

Examples citedExamples referenced in the policy and update history include vaginal swab panels (SmartJane™), urine screening panels (UroSwab®), and MicroGenDX qPCR+NGS

Policy change historyStatement regarding non‑reimbursability of general screening panels was clarified/maintained through policy updates (see Policy Update History)

Provider Responsibilities and Billing Guidance

Documentation Required

Documentation and claim review requirements

Providers are responsible for submission of accurate documentation of services performed and are expected to submit claims using valid code combinations; claims are subject to code edit protocols and review against plan documents, provider contracts, medical policies, clinical payment and coding policies, and coding software logic. Upon request, the provider is urged to submit any additional documentation for claim review.

Billing Rule

Prior authorization / billing applicability and code changes

Policy Update History lists multiple CPT/HCPCS (U-code) additions and removals across several update dates and clarifies the policy applies to outpatient testing; providers should bill using the current code set and follow the outpatient-only applicability.

08/01/2025 entry: Added codes 0590U and 0593U (effective 10/01/2025).
01/23/2025 entry: Added codes 0202U, 0223U, 0225U, 0531U.
11/19/2024 entry: Added CPT code 0528U (effective 01/01/2025).
10/30/2024 entry: Added codes 0441U, 0442U, 0480U, 0504U; removed codes 0151U and 0416U; document clarified policy is specific to outpatient testing.

Policy Update History

2025-08-01code_additionLatest

Added codes 0590U and 0593U (effective 10/01/2025).

2025-01-23code_addition

Added codes 0202U, 0223U, 0225U, and 0531U (summary notes effective 04/15/2025).

2024-11-19code_addition

Added new CPT code 0528U (effective 01/01/2025).

2024-10-30policy_revision

Document updated with literature review; reimbursement information revised to specify the policy is specific to outpatient testing and statements revised; codes 0441U, 0442U, 0480U, 0504U were added and codes 0151U and 0416U were removed.

2024-03-01code_addition

Added code 0416U.

2023-11-01policy_revision

Removed prior statement disallowing molecular-based panel testing for general screening and added specific examples (e.g., GENETWORx tests) and clarification that such screening tests are not reimbursable.

2022-11-01policy_creation

Policy created as new policy (initial effective date).